This portal contains de-identified clinical data for research purposes only. All patient identifiers have been removed per HIPAA Safe Harbor guidelines.
Clinical Summary Report — Study ID: MDP-2026-04417
| Study Type | Retrospective Cohort Analysis |
| Population | N=2,847 adults, ages 35-72 |
| Condition | Type 2 Diabetes Mellitus with cardiovascular comorbidity |
| Primary Endpoint | HbA1c reduction at 12 months |
| Mean Baseline HbA1c | 8.7% (SD 1.3) |
| Mean Follow-up HbA1c | 7.1% (SD 0.9) |
| p-value | <0.001 |
Adverse Events Summary
| Event | Treatment (n=1,423) | Control (n=1,424) |
|---|
| Hypoglycemia (Grade 2+) | 3.2% | 1.1% |
| GI disturbance | 12.8% | 4.2% |
| Weight change (mean) | -2.3 kg | +0.8 kg |
| Cardiovascular event | 1.4% | 2.1% |
Data extracted from electronic health records across 14 participating institutions. IRB approval: MDP-IRB-2025-0892. ClinicalTrials.gov: NCT05891234.
Lab Results Panel — Reference Range Report
| Test | Result | Reference Range | Flag |
|---|
| Glucose, Fasting | 142 mg/dL | 70-100 | HIGH |
| Creatinine | 1.1 mg/dL | 0.7-1.3 | Normal |
| eGFR | 78 mL/min | >60 | Normal |
| Total Cholesterol | 238 mg/dL | <200 | HIGH |
| LDL | 156 mg/dL | <100 | HIGH |
| HDL | 42 mg/dL | >40 | Borderline |
| Triglycerides | 201 mg/dL | <150 | HIGH |
| TSH | 2.4 mIU/L | 0.4-4.0 | Normal |